{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+Age-Related+Macular+Degeneration+%28nAMD%29+Wet+AMD&page=2",
    "query": {
      "condition": "Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+Age-Related+Macular+Degeneration+%28nAMD%29+Wet+AMD&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+Age-Related+Macular+Degeneration+%28nAMD%29+Wet+AMD&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T03:49:17.500Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06864988",
      "title": "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Neovascularization Secondary to Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "4D-150 IVT (3E10 vg/eye)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "4D Molecular Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2025-03-03",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-10T03:49:17.500Z",
      "location_count": 91,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06864988"
    },
    {
      "nct_id": "NCT06817343",
      "title": "A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)",
        "Neovascular (Wet) Age-related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "Aflibercept (2.0 mg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Exegenesis Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2024-09-10",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-10-10T03:49:17.500Z",
      "location_count": 2,
      "location_summary": "Reno, Nevada • Erie, Pennsylvania",
      "locations": [
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06817343"
    },
    {
      "nct_id": "NCT07064759",
      "title": "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "4D-150 IVT (3E10 vg/eye)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "4D Molecular Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2025-07-22",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-10-10T03:49:17.500Z",
      "location_count": 54,
      "location_summary": "Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07064759"
    },
    {
      "nct_id": "NCT04645212",
      "title": "Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Wet Age-related Macular Degeneration",
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ADVM-022",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2020-12-14",
      "completion_date": "2030-06-26",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-10-10T03:49:17.500Z",
      "location_count": 9,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04645212"
    },
    {
      "nct_id": "NCT03999801",
      "title": "Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RGX-314",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 865,
      "start_date": "2019-05-31",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-10-10T03:49:17.500Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03999801"
    },
    {
      "nct_id": "NCT04005352",
      "title": "Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Brolucizumab 6 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aflibercept 2 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 734,
      "start_date": "2019-09-25",
      "completion_date": "2022-09-09",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-10-10T03:49:17.500Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04005352"
    },
    {
      "nct_id": "NCT05536973",
      "title": "Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ADVM-022",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2022-08-23",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-10-10T03:49:17.500Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05536973"
    },
    {
      "nct_id": "NCT03927690",
      "title": "Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "LKA651",
          "type": "DRUG"
        },
        {
          "name": "Lucentis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 91,
      "start_date": "2019-05-24",
      "completion_date": "2022-08-31",
      "has_results": true,
      "last_update_posted_date": "2024-06-20",
      "last_synced_at": "2026-10-10T03:49:17.500Z",
      "location_count": 7,
      "location_summary": "Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "‘Aiea",
          "state": "Hawaii"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03927690"
    },
    {
      "nct_id": "NCT05989126",
      "title": "Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)",
        "Neovascular Age-Related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "aflibercept 8 mg PFS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2024-04-15",
      "completion_date": "2024-05-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-10T03:49:17.500Z",
      "location_count": 2,
      "location_summary": "Bellaire, Texas • The Woodlands, Texas",
      "locations": [
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05989126"
    },
    {
      "nct_id": "NCT06856577",
      "title": "Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)",
        "Wet AMD"
      ],
      "interventions": [
        {
          "name": "Ixo-vec",
          "type": "GENETIC"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2025-02-28",
      "completion_date": "2030-11-23",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-10T03:49:17.500Z",
      "location_count": 75,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06856577"
    }
  ]
}